Highest quality for dry powder inhalation
MEGGLE has it.
The right lactose product for dry powder inhalation
InhaLac® stands for a lactose, which is, in particular, suitable for use in pulmonary and nasal drug delivery.
Inhalation aerosols offer the potential for needle-free systemic delivery of small molecule drugs as well as therapeutic peptides and proteins. An industry standard in dry powder inhalation formulation development, lactose monohydrate is used safely in DPI formulations. Using lactose as an excipient not only improves performance efficiency of the inhaler, but also facilitates powder handling during production. Effective performance of a dry powder inhaler largely depends on the carrier material used for the drug formulation.
Lactose: Carrier of API
Customization has been seen for MEGGLE products, traditionally used for the oral route of administration but is especially important when it comes to the inhalation route of administration, in particular dry powder inhaler (DPI), where lactose plays a predominant role as carrier for the active pharmaceutical ingredient (API) facilitating its delivery to the lower part of lung.
Our Service: Customized lactose for DPI
As DPI development is an interplay between inhalation device, API-properties and lactose carrier, a customized lactose which is tailored in particle size distribution, and surface property, may provide a competitive advantage, when the DPI-drug-development can be achieved in time and on target. Especially increasing the API’s fine particle fraction (FPF) through profound lactose carrier design and subsequently suffering less API loss can be a major improvement and marks successful drug commercialization.
MEGGLE has been active in this field for decades, and therefore has gained a tremendous amount of expertise, which the customer immediately benefits from. It is more than fair to say, that MEGGLE enabled successful products through its customized products for originators and generic companies alike.
Important: Highly controlled production process
In Dry Powder Inhalation (DPI) formulations, the excipient not only acts as a filler but also contributes to the performance features of the DPI. An extensive knowledge of the physico-chemical properties is a prerequisite to guarantee the functionality and safety of the DPI. This includes an established and well-investigated production process. All InhaLac® grades are produced via crystallization and subsequent sieving or milling. The optimized and standardized production process consistently ensures the highest production quality.
With our highly controlled production process different high quality grades for inhalation are obtained, providing an adequate range of particle.
MEGGLE´s lactose grades suitable for DPI are available under the trade names
InhaLac® 70, InhaLac® 120, InhaLac® 140, InhaLac® 150, InhaLac® 160, InhaLac® 180, InhaLac® 230, InhaLac® 240, InhaLac® 251, InhaLac® 300, InhaLac® 400 and InhaLac® 500
Information / Sample request:
MEGGLE has it.
The right lactose product for dry powder inhalation
InhaLac® stands for a lactose, which is, in particular, suitable for use in pulmonary and nasal drug delivery.
Inhalation aerosols offer the potential for needle-free systemic delivery of small molecule drugs as well as therapeutic peptides and proteins. An industry standard in dry powder inhalation formulation development, lactose monohydrate is used safely in DPI formulations. Using lactose as an excipient not only improves performance efficiency of the inhaler, but also facilitates powder handling during production. Effective performance of a dry powder inhaler largely depends on the carrier material used for the drug formulation.
Lactose: Carrier of API
Customization has been seen for MEGGLE products, traditionally used for the oral route of administration but is especially important when it comes to the inhalation route of administration, in particular dry powder inhaler (DPI), where lactose plays a predominant role as carrier for the active pharmaceutical ingredient (API) facilitating its delivery to the lower part of lung.
Our Service: Customized lactose for DPI
As DPI development is an interplay between inhalation device, API-properties and lactose carrier, a customized lactose which is tailored in particle size distribution, and surface property, may provide a competitive advantage, when the DPI-drug-development can be achieved in time and on target. Especially increasing the API’s fine particle fraction (FPF) through profound lactose carrier design and subsequently suffering less API loss can be a major improvement and marks successful drug commercialization.
MEGGLE has been active in this field for decades, and therefore has gained a tremendous amount of expertise, which the customer immediately benefits from. It is more than fair to say, that MEGGLE enabled successful products through its customized products for originators and generic companies alike.
Important: Highly controlled production process
In Dry Powder Inhalation (DPI) formulations, the excipient not only acts as a filler but also contributes to the performance features of the DPI. An extensive knowledge of the physio-chemical properties is a prerequisite to guarantee the functionality and safety of the DPI. This includes an established and well-investigated production process. All InhaLac® grades are produced via crystallization and subsequent sieving or milling. The optimized and standardized production process consistently ensures the highest production quality.
With our highly controlled production process different high quality grades for inhalation are obtained, providing an adequate range of particle.
MEGGLE´s lactose grades suitable for DPI are available under the trade names
InhaLac® 70, InhaLac® 120, InhaLac® 140, InhaLac® 150, InhaLac® 160, InhaLac® 180, InhaLac® 230, InhaLac® 240, InhaLac® 251, InhaLac® 300, InhaLac® 400 and InhaLac® 500